<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210413050952N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-28</date_registration>
      <primary_sponsor>Dastavard-e-Sina Co.</primary_sponsor>
      <public_title>Evaluation of safety and efficacy of CardiaMed heart valve prosthesis in a multicentral study on patients undergoing open heart valve surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of safety and efficacy of CardiaMed heart valve prosthesis in a multicentral study on patients undergoing open heart valve surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55754</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patient selection will be performed based on inclusion and exclusion criteria. Each center will use simple randomization to enroll patients. The randomization will be based on stratified randomization so that either of centers will randomly enroll patients into study groups, including CardiaMed valve and St Jude valve. The stratification of sample size will be based on the centers’ surgery volume so that Rajaie will enroll 60 patients and two other centers will enroll rest of cases, 20 patients in each center. The randomization method will be as simple randomization. All patients will be marked using a table of random numbers. The assignment of patients into three centers will be randomly done from number 0 to 100 so that 60, 20, and 20 patients will be randomly assigned into three centers, respectively. Then, each center will enroll assigned patients into two groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Rheumatic heart disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: CardiaMed mechanical valve - In this group a CardiaMed mechanical valve (CardiaMed; Penza, Russia) will be implemented via an open heart surgery in the mitral valve position. During a general anesthesia, the rheumatic mitral valve will be excised during open surgery and the CardiaMed mechanical valve will be implanted instead. Intervention 2: Control group: St Jude mechanical valve - In this group a St Jude mechanical valve (St. Jude Medical, Inc., St. Paul, Minn) will be implemented via an open heart surgery in the mitral valve position. During a general anesthesia, the rheumatic mitral valve will be excised during open surgery and the St Jude mechanical valve will be implanted instead.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After making data anonymous, it can be shared.

When:
At least, one year after study publication

To whom:
With researchers in the similar field via corresponding author after obtaining permission from ethics committee of main study center

Conditions:
Only for meta-analysis studies

Where to obtain:
Contact with corresponding author

How to obtain:
Contact with corresponding author and after obtaining permission from ethics committee of main study center

Comments:
None</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Gholamreza Omrani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, Rajaie CMRC, Hashemi Rafsanjani Highway and Vali-e-Asr St. cross-sections</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 2392 3061</telephone>
        <email>omrani@rhc.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Gholamreza Omrani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, Rajaie CMRC, Hashemi Rafsanjani Highway and Vali-e-Asr St. cross-sections</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 2392 2135</telephone>
        <email>omrani@rhc.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate for mechanical valve replacement due to rheumatic heart valve disease
Isolated mitral valve replacement</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients undergoing re-do surgeries
Patients with left ventricular ejection fraction ≤35%
Concomitant coronary artery bypasses graft surgery
Concomitant other valve surgeries
Patients suspicious for native valve endocarditis
Patients with contraindicated warfarin consumption</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I01</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Rheumatic fever with heart involvement</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: CardiaMed mechanical valve - In this group a CardiaMed mechanical valve (CardiaMed; Penza, Russia) will be implemented via an open heart surgery in the mitral valve position. During a general anesthesia, the rheumatic mitral valve will be excised during open surgery and the CardiaMed mechanical valve will be implanted instead.</i_keyword>
      <i_keyword>Control group: St Jude mechanical valve - In this group a St Jude mechanical valve (St. Jude Medical, Inc., St. Paul, Minn) will be implemented via an open heart surgery in the mitral valve position. During a general anesthesia, the rheumatic mitral valve will be excised during open surgery and the St Jude mechanical valve will be implanted instead.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Valvular function. Timepoint: Preoperative, Early postoperative, 6 months postoperative, 1 year postoperative. Method of measurement: Echocardiography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Bleeding. Timepoint: Postoperative and 1 year after surgery. Method of measurement: Physical examination and checking INR.</sec_outcome>
      <sec_outcome>Heart valve re-operation. Timepoint: Postoperative and 1 year after surgery. Method of measurement: Physical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dastavard-e-Sina Co.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-26</approval_date>
        <contact_name>Rajaie Cardiovascular Medical and Research Center</contact_name>
        <contact_address>No 1, Rajaie CMRC, Hashemi Rafsanjani Highway and Vali-e-Asr St. cross-section, Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
